Tofacitinib can treat erectile dysfunction.

Tofacitinib alone can improve severe erectile dysfunction (ED) and quality of life in men with rheumatoid arthritis.

Improved quality of life:

During treatment with Tofacitinib, patients' disease activity decreased and health-related quality of life improved.

Potential for side effects:

Although Tofacitinib is beneficial in some cases, it may still cause sexual dysfunction or other systemic consequences, which requires further study.

Potential benefits:

Some studies have found that Tofacitinib may have a positive effect on erectile function in some patients, especially those with ED caused by diseases such as rheumatoid arthritis.

Mechanism:

Tofacitinib may improve hemodynamics and neurological function associated with ED by inhibiting inflammatory response.

Side effects:

Despite its potential benefits, Tofacitinib may also cause some side effects, including increased risk of infection and other systemic effects, which may indirectly affect sexual function.

Further research:

More clinical studies are needed to verify the specific effects of Tofacitinib on erectile dysfunction, and to confirm its effectiveness and safety.

We aimed to explore the effect of Tofacitinib on erectile dysfunction (ED), as well as disease activity and health related quality of life in male patients with rheumatoid arthritis (RA). Forty eight male RA patients with ED were included. We had recored demographic and clinical data at baseline and the patient's treatment for six months. Disease activity was evaluated with the disease activity score on 28 joints (DAS28), quality of life with Health Assessment Questionnaire—Disability Index (HAQ-DI) and ED with International Index of Erectile Function—5 (IIEF-5).

According to the IIEF-5, 17 (35.4%) patients had severe ED, 10 (20.8%) patients moderate ED, 10 (20.8%) patients mild to moderate ED and 11 (22.9%) patients mild ED. For the entire patient group, baseline median IIEF-5 score was significantly increased from 9.35 (5.30–19.40) to 9.90 (5.20–24.90), baseline median DAS28 was significantly decreased from 5.65 (4.80–6.70) to 5.00 (2.40–6.40), HAQ-DI from 1.70 (1.10–2.40) to 1.15 (0.40–2.20) at 6th month of treatment (all p value < 0.001). Also, quantitative change in IIEF-5 was significantly correlated with changes in DAS28 (r: − 0.735, p < 0.001) and HAQ-DI (r: − 0.700, p < 0.001). Tofacitinib monotherapy may improve ED severity and as well as disease activity and health related quality of life in male patients with RA complaining of ED.